Last update Dec. 28, 2023

Morniflumate

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Niflumic acid is a cyclooxygenase-2 inhibitor, derived from nicotinic acid and the main metabolite of morniflumate. It has non-steroidal anti-inflammatory properties (NSAID), used to relieve inflammation, pain and edema in acute and chronic inflammatory conditions (rheumatoid arthritis, osteoarthritis and post-operative and post-traumatic events). Oral administration 3 to 4 times daily and typically as an ointment. Morniflumate is the morpholinoethyl ester of niflumic acid, with similar properties.

According to manufacturer's data, its excretion in breast milk is minimal, being the concentration reached in milk one hundredth of the plasma concentration. (AEMPS 2023)

Its high percentage of binding to plasma proteins makes it unlikely that significant amounts will pass into milk. 

Given the scarcity of published data on this drug and breastfeeding, it may be safer to use anti-inflammatory drugs of proven safety in breastfeeding.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Morniflumate is also known as Niflumic Acid.


Morniflumate in other languages or writings:

Tradenames

Main tradenames from several countries containing Morniflumate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 283 / 395 daltons
Protein Binding 90 %
VD 0.12 l/Kg
Tmax 2 hours
2 - 2.5 hours
M/P ratio 0.01 -

References

  1. AEMPS. Ácido niflúmico. Ficha técnica 2023 Full text (in our servers)
  2. Alessandri JL, Abossolo T, Reynaud I, Montbrun A, Sommer JC, Tilmont P. [Non-steroidal anti-inflammatory agents and pregnancy. A study of renal and digestive toxicity of niflumic acid in the perinatal period]. J Gynecol Obstet Biol Reprod (Paris). 1994 Abstract
  3. Chevallier B, Baudet V, Doumaz Y, Renaud C, Costil J. [Neonatal renal insufficiency secondary to niflumic acid administration in pregnancy]. Arch Fr Pediatr. 1992 Abstract
  4. Houin G, Tremblay D, Bree F, Dufour A, Ledudal P, Tillement JP. The pharmacokinetics and availability of niflumic acid in humans. Int J Clin Pharmacol Ther Toxicol. 1983 Abstract

Total visits

5,154

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM